News Archive

The reverse mergers are flowing. Q32 Bio will take Homology Medicines’ place on the Nasdaq, the companies said Thursday morning, and the biologics maker expects to have about $115 million at the time their deal closes, likely in the first quarter of 2024.

Triveni Bio has raised $92 million in a Series A financing round as it aims to move its atopic dermatitis antibody into the clinic.

A new biotechnology company has raised $245 million in a Series A financing round on the promise of an asthma drug that only needs to be taken twice a year.

Intellia Therapeutics has received the green light to study its in vivo CRISPR-based gene editing therapy in the U.S., positioning it to start a phase 3 trial of the Regeneron-partnered candidate by the end of the year.

As we enter the final leg of 2023, navigating the investment market in biotech continues to be fraught with twists and turns. The IPO market remains tight; there have been a few notable IPOs with mixed performance, a few significant clinical and regulatory successes and even attractive M&A.